Hodgkin Disease Transplantation Therapy (TEXT) 2013
Current status of hematopoietic stem cell transplantation in patients with refractory or
relapse hodgkin lymphoma
Although the high response rates, approximately 10% of patients with early-stage Hodgkin
Lymphoma (HL) and 20% with advanced disease will be refractory to initial treatment or
relapse after a first complete response [1-3]. The strategy for management of relapsed or
refractory disease is to deliver salvage chemotherapy, followed by high-dose chemotherapy
and autologous stem-cell transplantation (AutoSCT) in responding patients [4,5].